Hanmi Pharm.

At a glance

Hanmi Pharm. filed 148 disclosures in the last 12 months, including 67 insider, 8 5% holder, 4 earnings, 3 buyback and 2 contract. The most recent key filing was on Oct 27.

Revenue for 2025 was ₩1.55T, up 3.5% on 2024. Operating margin was 16.7% against 14.5% a year earlier. Debt was 50% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩860B and operating profit of ₩185B.

The 2025 annual report lists 2,382 employees with an average tenure of 8.9 years and average pay of ₩86.4M, #327 of 2,191 listed companies by average pay. Its 10 directors and auditors were paid ₩230M each on average. It paid ₩2,000 per common share in cash dividends, against ₩1,250 a year earlier (+60%). 한미사이언스(주) and related parties held 50.38% at year end.

Of 5 recent 5%+ holder reports, 0 raised and 3 cut a stake; the largest stake reported was 50.08% on Aug 12.

From the 2025 annual report

Staff: 2,382 (1,680 men, 702 women), of whom 63 on fixed-term contracts. Total pay for the year: ₩206B. Directors and auditors: 10, paid ₩2.3B in total.

Dividends (common shares)

Largest shareholder

한미사이언스(주) holds 41.42%; with 4 related parties the group holds 50.38% of common shares at year end (from 50.56% at the start of the year).

Individuals paid ₩500M or more

Auditor: 안진회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

New contracts, last 12 months

2 new supply contracts worth 8% of the revenue stated in the filings.

Amended amounts replace the originals. Subsidiary contracts and terminations are excluded.

Financial summary

5%+ holder reports